Katherine Arbour is the Executive Director, Global Clinical Data Management at Alexion Pharmaceuticals, which develops medicines for patients with rare diseases. Prior to joining Alexion, Arbour was the Executive Director (Head) of Clinical Data Management at Moderna Therapeutics, a company that develops synthetic mRNA platform technology for use in vaccines, rare diseases, and personalized cancer treatments.
Prior to joining Moderna Therapeutics, Arbour was Senior Director, Clinical Data Management at ARIAD Pharmaceuticals, an oncology company that developed small-molecule medicines to transform the lives of cancer patients. For more than nine years, she had developed the data collection initiatives for the global development of the leukemia medicine Iclusig® (ponatinib) and the non-small cell lung cancer breakthrough medicine, Alunbrig® (brigatinib).
Prior to joining ARIAD Pharmaceuticals, Arbour led a variety of projects and project teams in the area of data management at contract research organizations, which included the development of a variety of medicinal products and medical devices.
Arbour received her master of liberal arts in biotechnology from the Harvard Extension School in 2011. In the 2012 spring semester, she introduced the elements of clinical investigation course at the Extension School and had continued to teach clinical trial research until 2019. She also earned a master of arts in biopsychology from the University of British Columbia, Vancouver, Canada, and a bachelor of arts, magna cum laude, with a major in psychology and minor in biology from the State University of New York at Plattsburgh.